Mass spectrometry in cerebrospinal fluid uncovers association of glycolysis biomarkers with Alzheimer's disease in a large clinical sample.

MLA

de Geus, Matthijs B., et al. “Mass Spectrometry in Cerebrospinal Fluid Uncovers Association of Glycolysis Biomarkers with Alzheimer’s Disease in a Large Clinical Sample.” Scientific Reports, vol. 13, no. 1, Dec. 2023, pp. 1–14. EBSCOhost, https://doi.org/10.1038/s41598-023-49440-3.

APA

de Geus, M. B., Leslie, S. N., Lam, T., Wang, W., Roux-Dalvai, F., Droit, A., Kivisakk, P., Nairn, A. C., Arnold, S. E., & Carlyle, B. C. (2023). Mass spectrometry in cerebrospinal fluid uncovers association of glycolysis biomarkers with Alzheimer’s disease in a large clinical sample. Scientific Reports, 13(1), 1–14. https://doi.org/10.1038/s41598-023-49440-3

Chicago

de Geus, Matthijs B., Shannon N. Leslie, TuKiet Lam, Weiwei Wang, Florence Roux-Dalvai, Arnaud Droit, Pia Kivisakk, Angus C. Nairn, Steven E. Arnold, and Becky C. Carlyle. 2023. “Mass Spectrometry in Cerebrospinal Fluid Uncovers Association of Glycolysis Biomarkers with Alzheimer’s Disease in a Large Clinical Sample.” Scientific Reports 13 (1): 1–14. doi:10.1038/s41598-023-49440-3.